The etiologies of kidney allograft de novo TMA include calcineurin inhibitors (CNIs), mammalian target of rapamycin inhibitors, ischemia-reperfusion injury, antibody-mediated rejection (AMR), viral infection, thrombotic thrombocytopenic purpura, and atypical hemolytic uremic syndrome (aHUS). This evidence concerns the gene MTOR and atypical hemolytic-uremic syndrome.